Clinical OMICS

MAR-APR 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 14 of 47 March/April 2017 Clinical OMICs 13 has given us confidence in the very technology, and certainly our methods . Also importantly, the bioinformatics, the actual analysis done in our collabo- ration with the engineers that we work with, all seem to work very well," Dr. Arasaradnam said . FAIMS is a variant of ion mobility spectrometry, a method of distinguish- ing charged gaseous molecules based on differences in the speed that they move through a buffer gas under the influence of an oscillating electric field. Following ionization, VOC ions pass through channels across which an asymmetric radio frequency (RF) field is applied. Under the first portion of the waveform, ions will drift in one direction at a velocity based on their individual mobility in that electric field. As the field polarity is reversed, the ions change direction and speed . The mobility of the ions during the two parts of the waveform is rarely equal, resulting typically in a net drift towards one of the electrodes . In FAIMS, this net drift is corrected for by applying an additional DC volt- age or "compensation field," focusing specific ions through the device to the detector . The FAIMS device produces a compensation field spectrum for the transmission of all ions . Could the VOCs to be detected through InTERCEPT differ from one form of cancer to another? "This is a great question . The short answer is, no one knows for sure," Boyle said . "I think the kind of work- ing hypothesis that exists today is that you have some general cancer metabolic markers associated with the growth of the tumor, but actually you will also almost certainly have site-specific volatile markers. In col- orectal cancer, for instance, as the tumor grows in the colon, it starts to disrupt the local microbiome as well . And you see that reflected in changes in the metabolism as well . "Most likely, what we'll find is a combination of a general cancer marker with specific cancer type markers as well," Boyle added. Owlstone's ReCIVA breath sampler and Lonestar gas analyzer will be assessed in a clinical trial aimed at detecting colorectal cancer early from breath and urine samples. AdvanceIQ Network Provides Independent Oncology, Urology Practices with Improved Clinical Trial Access IntrinsiQ Specialty Solutions and ION Solutions, both a part of drug wholesaler AmerisourceBergen, have unveiled the AdvanceIQ Network, a resource for com- munity oncology and urology practices aimed at improving the ability of patients in the community setting to qualify for and enroll in targeted clinical trials. The new service will be made avail- able to the more than 5,300 community providers that are part of ION Solutions, a physician service organization serv- ing oncology practices, with the aim of reducing the time burden on practices that may prevent them from referring patients for clinical trials. " The launch of AdvanceIQ Network addresses one of healthcare's biggest challenges—access. As specialty care continues to grow, it's critically import- ant we create new pathways, through both innovation and partnerships, to connect patients to cutting-edge ther- apies found in clinical trials," said Susan Weidner, senior vice president at Intrin- siQ Specialty Solutions, a provider of medical oncology workflows and data analysis. Practices in the network select the types of research in which they would like to participate, and will provide access to de-identified patient informa- tion to the network. Clinical trial devel- opers can search AdvanceIQ to find practices treating patients who meet specific trial criteria. asiseeit/ Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAR-APR 2017